|Auxilium Pharmaceuticals Inc.|
640 Lee Road
United States - Map
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, develops and markets pharmaceutical products worldwide. It markets Testim, a topical 1% testosterone once-a-day gel for the treatment of hypogonadism; and XIAFLEX, an injectable clostridial collagenase enzyme for the treatment of Dupuytrens in adult patients with a palpable cord. The company is also developing XIAFLEX, which is in Phase III clinical trial for the treatment of Peyronies disease; and in Phase II clinical trial for the treatment of Adhesive Capsulitis, as well as in Phase II clinical trial for the treatment of edematous fibrosclerotic panniculopathy. In addition, it is developing a high concentration testosterone gel product. Further, the company has rights to pursue additional indications for collagenase clostridium histolyticum. Auxilium Pharmaceuticals, Inc. sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. The company was founded in 1999 and is headquartered in Chesterbrook, Pennsylvania.
|Auxilium Pharmaceuticals Inc.’s ISS Governance QuickScore as of May 1, 2013 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Adrian Adams ,
Chief Exec. Officer, Pres and Director
|Mr. James E. Fickenscher ,
Chief Financial Officer and Principal Accounting Officer
|Mr. Andrew I. Koven ,
Chief Admin. Officer, Exec. VP, Gen. Counsel and Sec.
|Mr. Alan J. Wills ,
Exec. VP of Corp. Devel.
|Dr. James Patrick Tursi M.D.,
Chief Medical Officer
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|